Consumer Discretionary · Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · CIK 1021561 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $5.23Day −1.13%Mkt cap $257MP/E (FY) 1.7×1Y −37.6%Off 52W high −64.2%Vol (1Y) 50.9%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,295 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Price impliesUNDEMANDING · −17.2% growth |
| Short interest8.6% of sh out |
| Days to cover6.0d |
| 13F net flow (QoQ)+3.55% |
| Top-10 13F concentration56.3% |
| Next report (est.)2026-08-06 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)1.7× |
| Sales (TTM)$1.44B |
| Earnings (TTM)$54.5M |
| ROE22.0% |
| Net margin10.8% |
| ROIC6.6% |
| YTD−44.7% |
| 1Y−37.6% |
| 3Y−80.2% |
| 5Y−88.4% |
| 10Y−86.3% |
| Since incept. (ann.)−4.6% |
Total return through 2026-07-30 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)50.9% |
| Ann. volatility (3Y)53.2% |
| Sharpe (1Y)−0.68 |
| Sharpe (3Y)−0.75 |
| Max drawdown (1Y)−60.6% |
| Max drawdown (3Y)−81.5% |
| Beta (3Y vs SPY)1.09 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 4.3M | $31M | 8.92% | −0.6% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.1M | $16M | 4.45% | −18.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.1M | $15M | 4.29% | new |
| AMERICAN CENTURY COMPANIES INC | 2.0M | $15M | 4.20% | +13.9% |
| Prescott Group Capital Management, L.L.C. | 1.8M | $13M | 3.73% | +3.5% |
| ACADIAN ASSET MANAGEMENT LLC | 1.8M | $13M | 3.66% | +166.2% |
| DIMENSIONAL FUND ADVISORS LP | 1.7M | $13M | 3.61% | +26.3% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.7M | $12M | 3.55% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | $0.04 | −98.1% | $320.6M | −12.0% |
| 2025-12-31 | 2026-02-12 | — | — | $370.3M | −16.9% |
| 2025-09-30 | 2025-11-06 | $0.34 | +100.0% | $364.2M | −15.3% |
| 2025-06-30 | 2025-08-07 | $0.43 | — | $386.1M | −12.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Wellness 46% · Beauty 38% · Other Product Lines 15%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Total debt / EBITDA1.90× |
| EPS growth 3Y15.4% |
| Sales growth 3Y−12.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
